Wednesday, September 25, 2024 8:09:32 PM
LC,
I doubt that much of your statement is close to accurate, but even if I believed every word that you said, your implication is still illogical…
Why would somebody holding 130 million shares not be acting in their own best interest to maximize the value potential of those shares? I would.
You expect us to believe that the Harvard lawyer doesn’t know where her greatest wealth opportunity can be found? She is wealthy already, but she is not stupid. Do the math, sir 😶
“Published statements and other publicly available documents affirm that Northwest Biotherapeutics is strongly committed to transparency, regulatory compliance, and the achievement of its long-term business objectives, as evidenced by its ongoing progress with regulatory authorities in both commercial approval and manufacturing. Moreover, it is important to recognize that the leadership of Northwest Biotherapeutics, including senior management, are significant shareholders in the company. As such, they have a direct, vested interest in building assets of real value that will propel the share price upward. It is illogical to suggest that the leadership would act in anything other than good faith, as their personal financial interests are inherently aligned with the success of the company and the realization of an exceptionally high share price. This alignment further reinforces the leadership's commitment to the company's sustained growth and value creation for all shareholders.”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175094676
I doubt that much of your statement is close to accurate, but even if I believed every word that you said, your implication is still illogical…
Why would somebody holding 130 million shares not be acting in their own best interest to maximize the value potential of those shares? I would.
You expect us to believe that the Harvard lawyer doesn’t know where her greatest wealth opportunity can be found? She is wealthy already, but she is not stupid. Do the math, sir 😶
“Published statements and other publicly available documents affirm that Northwest Biotherapeutics is strongly committed to transparency, regulatory compliance, and the achievement of its long-term business objectives, as evidenced by its ongoing progress with regulatory authorities in both commercial approval and manufacturing. Moreover, it is important to recognize that the leadership of Northwest Biotherapeutics, including senior management, are significant shareholders in the company. As such, they have a direct, vested interest in building assets of real value that will propel the share price upward. It is illogical to suggest that the leadership would act in anything other than good faith, as their personal financial interests are inherently aligned with the success of the company and the realization of an exceptionally high share price. This alignment further reinforces the leadership's commitment to the company's sustained growth and value creation for all shareholders.”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175094676
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
